- Home
- SOWG vs LSTA Comparison
SOWG vs LSTA Comparison
Compare SOWG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- LSTA
- Stock Information
- Founded
- SOWG 2010
- LSTA 1980
- Country
- SOWG United States
- LSTA United States
- Employees
- SOWG N/A
- LSTA N/A
- Industry
- SOWG Packaged Foods
- LSTA Misc Health and Biotechnology Services
- Sector
- SOWG Consumer Staples
- LSTA Health Care
- Exchange
- SOWG Nasdaq
- LSTA Nasdaq
- Market Cap
- SOWG 22.6M
- LSTA 20.0M
- IPO Year
- SOWG N/A
- LSTA N/A
- Fundamental
- Price
- SOWG $2.43
- LSTA $2.32
- Analyst Decision
- SOWG Strong Buy
- LSTA Strong Buy
- Analyst Count
- SOWG 2
- LSTA 1
- Target Price
- SOWG $23.00
- LSTA $15.00
- AVG Volume (30 Days)
- SOWG 33.8K
- LSTA 17.8K
- Earning Date
- SOWG 03-21-2025
- LSTA 05-08-2025
- Dividend Yield
- SOWG N/A
- LSTA N/A
- EPS Growth
- SOWG N/A
- LSTA N/A
- EPS
- SOWG 0.21
- LSTA N/A
- Revenue
- SOWG $40,130,971.00
- LSTA $1,000,000.00
- Revenue This Year
- SOWG $122.17
- LSTA N/A
- Revenue Next Year
- SOWG N/A
- LSTA N/A
- P/E Ratio
- SOWG $11.63
- LSTA N/A
- Revenue Growth
- SOWG 508.45
- LSTA N/A
- 52 Week Low
- SOWG $1.98
- LSTA $2.05
- 52 Week High
- SOWG $24.83
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- SOWG 46.21
- LSTA 42.12
- Support Level
- SOWG $2.20
- LSTA $2.07
- Resistance Level
- SOWG $2.36
- LSTA $2.62
- Average True Range (ATR)
- SOWG 0.19
- LSTA 0.21
- MACD
- SOWG 0.01
- LSTA 0.01
- Stochastic Oscillator
- SOWG 47.13
- LSTA 47.37
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free granola products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.